Wir sind mit live! Mehr erfahren
18,90 USD
-0,35
1,82 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
18,90
0,00
0 %
1 Tag
-1,82 %
5 Tage
-4,35 %
1 Monat
-16,11 %
3 Monate
-5,97 %
6 Monate
25,75 %
Seit Jahresbeginn
-8,16 %
1 Jahr
-21,58 %
5 Jahre
-20,75 %
10 Jahre
-3,91 %
 

Profil: Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

Mitarbeiter: 5.795

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 36,4 %
Neutral 63,6 %
Negativ 0 %
Neutral
Seeking Alpha
letzten Monat
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
letzten Monat
Baron Global Durable Advantage ETF Q2 2026 Portfolio Activity
During the second quarter, we initiated three new positions: a leading software and semiconductor company, Broadcom, Samsung Electronics, and INNIO. We took advantage of inflows and market volatility to add to 36 existing positions. We also exited three investments – Indutrade, HDFC Bank, and Wix – reallocating to names in which we saw a more attractive risk-reward profile.
Baron Global Durable Advantage ETF Q2 2026 Portfolio Activity
Neutral
Business Wire
letzten Monat
Stevanato Group to Participate in Two Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.
Stevanato Group to Participate in Two Upcoming Investor Conferences
Positiv
Seeking Alpha
letzten Monat
Stevanato Group: Alina Validates The Container-To-Device Flywheel
Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships.
Stevanato Group: Alina Validates The Container-To-Device Flywheel
Positiv
MarketBeat
vor 2 Monaten
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Stevanato Group Q2 Earnings Call Highlights
Positiv
Zacks Investment Research
vor 2 Monaten
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neutral
Seeking Alpha
vor 2 Monaten
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Positiv
Zacks Investment Research
vor 2 Monaten
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
Stevanato Group (STVN) Q2 Earnings Top Estimates
Neutral
Business Wire
vor 2 Monaten
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Neutral
Business Wire
vor 2 Monaten
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Kursdiagramme mit Lightweight Charts™ umgesetzt